
Exact Sciences Surges to New Heights: 2024 Ends with Groundbreaking Advances
Exact Sciences surpassed expectations in 2024 with innovation and resilience, delivering 4.6 million cancer diagnostic test results. The company achieved an 11% increase in core revenue and remarkably expanded operating margins by 48%. Free cash flow doubled, underscoring Exact Sciences’ strong financial